173 related articles for article (PubMed ID: 37343205)
1. Erdafitinib's Road to Approval and Use in Urothelial Carcinoma.
Hanna K
Oncology (Williston Park); 2023 Jun; 37(6):260-261. PubMed ID: 37343205
[No Abstract] [Full Text] [Related]
2. [Drug approval: Enfortumab vedotin-advanced urothelial carcinoma (which have previously received platinum-containing chemotherapy and immunotherapy)].
Matte P; Campedel L
Bull Cancer; 2022; 109(7-8):738-740. PubMed ID: 35606195
[No Abstract] [Full Text] [Related]
3. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
Zhu X; Koshkin VS
Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
[TBL] [Abstract][Full Text] [Related]
4. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
Taguchi S; Kawai T; Nakagawa T; Kume H
BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
[No Abstract] [Full Text] [Related]
5. Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma.
Miron B; Geynisman DM
Eur Urol; 2022 Oct; 82(4):374-376. PubMed ID: 35752503
[No Abstract] [Full Text] [Related]
6. Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
Benjamin DJ; Lythgoe MP; Rezazadeh A
BJU Int; 2023 Jun; 131(6):691-693. PubMed ID: 36877951
[No Abstract] [Full Text] [Related]
7. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Tilgener C; Bedke J
Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
[No Abstract] [Full Text] [Related]
8. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zschäbitz S; Niegisch G
Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
[TBL] [Abstract][Full Text] [Related]
9. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
[No Abstract] [Full Text] [Related]
10. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
Bellmunt J; Nadal R
Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
[TBL] [Abstract][Full Text] [Related]
11. A new era in the treatment of urothelial carcinoma.
Faltas B
Urol Oncol; 2023 Oct; 41(10):395-397. PubMed ID: 37833099
[TBL] [Abstract][Full Text] [Related]
12. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
Rexer H; Ohlmann CH; Gschwend J;
Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
[No Abstract] [Full Text] [Related]
13. Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Kondo T
Int J Urol; 2024 May; 31(5):560-561. PubMed ID: 38424666
[No Abstract] [Full Text] [Related]
14. Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Ishihara H; Takagi T
Int J Urol; 2024 May; 31(5):559-560. PubMed ID: 38366784
[No Abstract] [Full Text] [Related]
15. The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
Bertucci F; de Nonneville A; Finetti P; Cohendet A; Guille A; Mamessier E
Ann Oncol; 2024 May; 35(5):477-478. PubMed ID: 38364991
[No Abstract] [Full Text] [Related]
16. Enfortumab Vedotin in Advanced Urothelial Carcinoma.
Yeon SH; Lee HJ
N Engl J Med; 2021 Jul; 385(1):93. PubMed ID: 34192440
[No Abstract] [Full Text] [Related]
17. A new standard of care for advanced-stage urothelial carcinoma.
Sidaway P
Nat Rev Clin Oncol; 2024 May; 21(5):336. PubMed ID: 38509334
[No Abstract] [Full Text] [Related]
18. Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply.
Petrylak DP; Powles T; Rosenberg JE
N Engl J Med; 2021 Jul; 385(1):93-94. PubMed ID: 34192441
[No Abstract] [Full Text] [Related]
19. Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Bedke J; Maas M
Eur Urol; 2021 Aug; 80(2):257-258. PubMed ID: 33895011
[No Abstract] [Full Text] [Related]
20. Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.
Niegisch G
N Engl J Med; 2024 Mar; 390(10):944-946. PubMed ID: 38446680
[No Abstract] [Full Text] [Related]
[Next] [New Search]
